Recombinant human serum amyloid P in healthy volunteers and patients with pulmonary fibrosis

Fibrocytes in pulmonary fibrosis: a brief synopsis

“…There is increasing support for the hypothesis that fibrocytes differentiate into myofibroblasts, as has been demonstrated in vivo [33,38,41] and in vitro [24]. Serum amyloid P appears to be an inhibitor of fibrocyte differentiation and is currently being developed for IPF treatment [42]. More knowledge about fibrocyte biology in vivo is still needed before they can be confirmed as a major treatment target.…”

Bone marrow fibrosis in myelofibrosis: pathogenesis, prognosis and targeted strategies

“…82 Injections of PTX2 reduce fibrosis significantly in several animal models (pulmonary fibrosis, ischemic cardiac fibrosis, renal fibrosis). [83][84][85][86][87][88] On the other hand, PTX3 promotes human and murine fibrocyte differentiation. 81 PRM-151 is a recombinant PTX2 being actively investigated in the treatment of various fibrotic diseases including MF (NCT01981850).…”

“…However, EphA3 expression has been demonstrated in various hematologic and solid tumors. 88,89 In solid malignancies, EphA3 is preferentially expressed in tumor stroma, vasculature, and bone marrow-derived mesenchymal stem cells. 101 Data from Vail et al suggest that Eph is not ligated in stromal cells derived from the solid tumor so it is kinase-dormant.…”

Role of CXCL12/CXCR4-Mediated Circulating Fibrocytes in Pulmonary Fibrosis

“…Preclinical cell and animal experiments suggested that SAP could reduce bleomycin-induced lung fibrosis 38,[83][84][85] . Intravenous administration of recombinant form of human SAP (PRM-151) resulted in a 30-50% decrease in fibrocyte numbers 24 h post-dose in pulmonary fibrosis patients 86 . This first-in-class modulator of the fibrosis pathway has been granted orphan drug designation for myelofibrosis by FDA, and the phase 2 clinical trials ongoing (NCT01981850) 87 .…”